EDWARDS LIFESCIENCES CORP (EWL.DE) Stock Price & Overview
FRA:EWL • US28176E1082
The current stock price of EWL.DE is 69.99 EUR. Today EWL.DE is down by -3.46%. In the past month the price increased by 3.11%. In the past year, price increased by 8.97%.
EWL.DE Key Statistics
- Market Cap
- 40.615B
- P/E
- 31.81
- Fwd P/E
- 27.35
- EPS (TTM)
- 2.20
- Dividend Yield
- N/A
EWL.DE Stock Performance
EWL.DE Stock Chart
EWL.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to EWL.DE. When comparing the yearly performance of all stocks, EWL.DE is a bad performer in the overall market: 61.96% of all stocks are doing better.
EWL.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to EWL.DE. Both the health and profitability get an excellent rating, making EWL.DE a very profitable company, without any liquidiy or solvency issues.
EWL.DE Earnings
On February 10, 2026 EWL.DE reported an EPS of 0.58 and a revenue of 1.57B. The company missed EPS expectations (-8.84% surprise) and missed revenue expectations (-1.47% surprise).
EWL.DE Forecast & Estimates
43 analysts have analysed EWL.DE and the average price target is 81.61 EUR. This implies a price increase of 16.6% is expected in the next year compared to the current price of 69.99.
For the next year, analysts expect an EPS growth of 16.14% and a revenue growth 10.47% for EWL.DE
EWL.DE Groups
Sector & Classification
EWL.DE Financial Highlights
Over the last trailing twelve months EWL.DE reported a non-GAAP Earnings per Share(EPS) of 2.2. The EPS decreased by -2.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 23.25% | ||
| ROA | 10.31% | ||
| ROE | 13.4% | ||
| Debt/Equity | 0.06 |
EWL.DE Ownership
EWL.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 2M6 | MEDTRONIC PLC | 14.75 | 103.215B | ||
| SHL | SIEMENS HEALTHINEERS AG | 15.11 | 45.684B | ||
| 1PHIA | KONINKLIJKE PHILIPS NV | 17.51 | 25.662B | ||
| PHIA | KONINKLIJKE PHILIPS NV | 16.36 | 24.632B | ||
| PHI1 | KONINKLIJKE PHILIPS NV | 16.42 | 24.555B | ||
| BIM | BIOMERIEUX | 19.06 | 11.274B | ||
| DIA | DIASORIN SPA | 16.86 | 3.845B | ||
| OBCK | OTTOBOCK SE & CO KGAA | 18.63 | 3.66B | ||
| AFX | CARL ZEISS MEDITEC AG - BR | 10.61 | 2.27B | ||
| DRW3 | DRAEGERWERK AG - PREF | 11.95 | 1.653B | ||
| DRW8 | DRAEGERWERK AG | 9.87 | 1.343B | ||
| ELN | EL.EN. SPA | 21.21 | 1.065B | ||
| EUZ | ECKERT & ZIEGLER SE | 18.11 | 952.165M |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About EWL.DE
Company Profile
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Company Info
EDWARDS LIFESCIENCES CORP
One Edwards Way
Irvine CALIFORNIA US
Employees: 15800
Phone: 13026587581
EDWARDS LIFESCIENCES CORP / EWL.DE FAQ
Can you describe the business of EDWARDS LIFESCIENCES CORP?
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
What is the stock price of EDWARDS LIFESCIENCES CORP today?
The current stock price of EWL.DE is 69.99 EUR. The price decreased by -3.46% in the last trading session.
Does EWL stock pay dividends?
EWL.DE does not pay a dividend.
How is the ChartMill rating for EDWARDS LIFESCIENCES CORP?
EWL.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the analyst forecast for EWL.DE stock?
43 analysts have analysed EWL.DE and the average price target is 81.61 EUR. This implies a price increase of 16.6% is expected in the next year compared to the current price of 69.99.
What sector and industry does EDWARDS LIFESCIENCES CORP belong to?
EDWARDS LIFESCIENCES CORP (EWL.DE) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Should I buy EWL stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EWL.DE.